Telix Pharmaceuticals Reports Strong Q2 Results and Updates FY2026 Outlook
Telix Pharmaceuticals (TLX) reported second-quarter revenue of $247 million, a 21.1% year-over-year increase that exceeded expectations by $26.32 million. The company's Precision Medicine segment saw continued strong growth with revenue reaching US$202 million, up 9% quarter-over-quarter and 30% year-over-year.
Topics: financial_results pharmaceuticals precision_medicine